SequelSEC

20/20 Biolabs, Inc. AIDX

Services-Testing Laboratories · CIK 0001139685 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$730.57K
Fiscal year ended 2026-06-30
Operating income
-$1.24M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

20/20 Biolabs, Inc. (AIDX) reported revenue of $730.57K and net income of -$1.51M for the fiscal year ended 2026-06-30. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from 20/20 Biolabs, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Testing Laboratories.

Income

20/20 Biolabs, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Revenue$730.57K$353.38K$956.25K$535.06K$553.82KUnavailable
Cost of revenue$425.84K$290.49K$680.77K$371.80K$388.02KUnavailable
Gross profit$304.73K$62.88K$275.48K$163.26K$165.80KUnavailable
Operating income-$1.24M-$1.44M-$1.71M-$845.67K-$772.18KUnavailable
Net income-$1.51M-$2.17M-$2.13M-$840.93K-$764.58KUnavailable
Research & development$257.63K$153.48K$261.61K$194.12K$136.83KUnavailable
Weighted-average diluted sharesshares 10.79Mshares 7.66MUnavailableshares 4.82Mshares 4.82MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.26$-0.28$-0.43$-0.17$-0.16Unavailable
Selling, general & administrative$1.29M$1.35M$1.73M$814.81K$801.14KUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

20/20 Biolabs, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Cash & equivalents$4.55M$4.22M$1.03MUnavailableUnavailable$1.78M
Total assets$6.12M$5.80M$4.14MUnavailableUnavailable$3.58M
Current assets$5.08M$4.70M$1.47MUnavailableUnavailable$2.03M
Total liabilities$2.96M$3.05M$4.16MUnavailableUnavailable$2.08M
Current liabilities$2.55M$2.58M$2.46MUnavailableUnavailable$1.36M
Total equity incl. NCI$1.62M$2.55M-$19.22K$351.61K$1.06M$1.51M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$111.04K$104.52K$116.22KUnavailableUnavailable$47.16K
Accounts receivable$291.49K$201.48K$199.95KUnavailableUnavailable$135.27K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.03M$980.49K$868.54KUnavailableUnavailable$372.30K

Cash flow

20/20 Biolabs, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Operating cash flow-$605.46K-$1.29M-$897.32K-$534.10K-$488.29KUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$7.50K-$5.35KUnavailableUnavailableUnavailableUnavailable
Financing cash flow$940.00K$4.49M$899.36K$0$262.34KUnavailable
Net change in cash$327.04K$3.19M$2.04K-$534.10K-$225.96KUnavailable
Stock-based compensation$371.30K$128.44K$256.88K$129.65K$129.65KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$12.30K$12.31K$29.95K$15.48K$17.82KUnavailable

Derived

20/20 Biolabs, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin41.7%17.8%28.8%30.5%29.9%Unavailable
Operating margin-170.3%-408.4%-179.1%-158.1%-139.4%Unavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue50.8%36.3%26.9%24.2%23.4%Unavailable
Current ratio1.99x1.82x0.60xUnavailableUnavailable1.50x
Revenue YoY growth36.5%-36.2%UnavailableUnavailableUnavailableUnavailable
Net margin-206.2%Unavailable-223.1%-157.2%UnavailableUnavailable
R&D / revenue35.3%43.4%27.4%36.3%24.7%Unavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AIDX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-03-31View SEC filing

Companies in the same industry

FUNI NEO ULS

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2026-06-30

Difference 1538608 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.